Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

Abstract

Trilok Shrivastava, Frits Van Rhee, Samer Al Hadidi Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USACorrespondence: Samer Al Hadidi, Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA, Email [email protected]: Relapsed/refractory multiple myeloma remains a challenging disease necessitating the development of more effective treatment options. In the past decade, myeloma therapies have made significant advancements with the introduction of new treatment modalities. One of the new major targets for these novel therapeutics has been B-cell maturation antigen (BCMA), which is expressed on mature B-lymphocytes and plasma cells. There are three main categories of BCMA-targeted therapies currently available, including bispecific antibodies (BsAbs), antibody drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies. In this review, we discuss the existing BCMA-targeted therapies and provide insights into currently available treatment and future developments, with a particular focus on clinical efficacy and common drug-related adverse events.Keywords: BCMA, multiple myeloma, bispecific antibody, BiTE, CAR T cells, B-cell maturation antigen

Keywords

• bcma
• multiple myeloma
• bispecific antibody
• bite
• car t cells
• b-cell maturation antigen.